Abstract
ALK+ tumors (2-7% of NSCLC) are sensitive to ALK tyrosine kinase inhibitors such as crizotinib (CRZ), although resistance invariably develops. Ceritinib (LDK378), a novel ALK inhibitor (ALKi), is more potent than CRZ in vitro and is effective in CRZ-resistant disease. Updated data from the ASCEND-1 study (NCT01283516) are presented with a focus on patients receiving ceritinib at the recommended dose of 750 mg/day and with a longer follow-up compared with prior presentation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
